D. Downey

Most-cited papers

1. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

   Obbina Ali Fatima Mustafa Sadia Hakam Alfie Nabeel Ashraf Abani Abbas Abbas Abbas Abbasi Abbass Abbott Abdal, O. Abani, A. Abbas, F. Abbas +496 more

   2021The Lancet1,685 citations Open access

   Semantic Scholar

   Save

2. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

   Eugenia Mustafa Sadia Alfie Ashraf Sherif Mohamed Basir Al Abaleke Abbas Abbasi Abbott Abdelaziz Abdelbadiee , E. Abaleke, M. Abbas, Sadia Abbasi +496 more

   2021The Lancet289 citations Open access

   Semantic Scholar

   Save

3. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

   O. A. F. J. K. M. S. H. A. Abani Abbas Abbas Abbas Abbas Abbas Abbasi Abbass, O. Abani, A. Abbas, F. Abbas +496 more

   2023The Lancet103 citations Open access

   Semantic Scholar

   Save

4. Future therapies for cystic fibrosis

   L. Allen, L. Allen, S. Carr, G. Davies +9 more

   2023Nature Communications99 citations Open access

   Semantic Scholar

   Save

5. Failure to conceive in women with CF is associated with pancreatic insufficiency and advancing age.

   M. Shteinberg, Adi Ben Lulu, D. Downey, Z. Blumenfeld +21 more

   2019Journal of Cystic Fibrosis64 citations Open access

   Semantic Scholar

   Save

6. The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis

   Caitlyn Harvey, S. Weldon, S. Elborn, D. Downey +1 more

   2022International Journal of Molecular Sciences51 citations Open access

   Semantic Scholar

   Save

7. Coinfection with Pseudomonas aeruginosa and Aspergillus fumigatus in cystic fibrosis

   K. Keown, A. Reid, J. Moore, C. Taggart +1 more

   2020European Respiratory Review51 citations Open access

   Semantic Scholar

   Save

8. Airway Inflammation and Host Responses in the Era of CFTR Modulators

   K. Keown, Ryan Brown, D. Doherty, C. Houston +8 more

   2020International Journal of Molecular Sciences47 citations Open access

   Semantic Scholar

   Save

9. Antimicrobial effect of dimethyl sulfoxide and N, N-Dimethylformamide on Mycobacterium abscessus: Implications for antimicrobial susceptibility testing

   Zara I Kirkwood, B. Millar, D. Downey, J. Moore

   2018International Journal of Mycobacteriology40 citations Open access

   Semantic Scholar

   Save

10. Community analysis and co-occurrence patterns in airway microbial communities during health and disease

    G. Einarsson, Jiangchao Zhao, J. Lipuma, D. Downey +2 more

    2019ERJ Open Research37 citations Open access

    Semantic Scholar

    Save

11. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.

    P. Flume, R. Biner, D. Downey, C. Brown +16 more

    2021The Lancet Respiratory Medicine36 citations Open access

    Semantic Scholar

    Save

12. Development of a core outcome set for trials investigating the long-term management of bronchiectasis

    Maureen Spargo, C. Ryan, D. Downey, C. Hughes

    2018Chronic Respiratory Disease31 citations Open access

    Semantic Scholar

    Save

13. Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe

    A. Jung, A. Orenti, F. Dunlevy, E. Aleksejeva +43 more

    2021ERJ Open Research29 citations Open access

    Semantic Scholar

    Save

14. Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study

    S. van Koningsbruggen-Rietschel, J. Davies, T. Pressler, R. Fischer +10 more

    2020ERJ Open Research26 citations Open access

    Semantic Scholar

    Save

15. Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis.

    J. Chmiel, P. Flume, D. Downey, A. J. Dozor +10 more

    2020Journal of Cystic Fibrosis25 citations Open access

    Semantic Scholar

    Save

16. Inflammation biomarkers in sputum for clinical trials in cystic fibrosis: current understanding and gaps in knowledge.

    A. Lepissier, C. Addy, K. Hayes, S. Noel +9 more

    2021Journal of Cystic Fibrosis24 citations Open access

    Semantic Scholar

    Save

17. Theratyping in cystic fibrosis

    K. Crawford, D. Downey

    2018Current opinion in pulmonary medicine22 citations Open access

    Semantic Scholar

    Save

18. Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis

    É. Vallières, K. Tumelty, M. Tunney, R. Hannah +3 more

    2017European Respiratory Journal22 citations Open access

    Semantic Scholar

    Save

19. ASSESSMENT OF STABILITY AND FLUCTUATIONS OF CULTURED LOWER AIRWAY BACTERIAL COMMUNITIES IN PEOPLE WITH CYSTIC FIBROSIS

    L. Sherrard, G. Einarsson, E. Johnston, K. O'Neill +10 more

    2019Journal of Cystic Fibrosis20 citations Open access

    Semantic Scholar

    Save

20. EMPIRE-CF STUDY: A PHASE 2 CLINICAL TRIAL OF LEUKOTRIENE A4 HYDROLASE INHIBITOR ACEBILUSTAT IN ADULT SUBJECTS WITH CYSTIC FIBROSIS

    J. Elborn, M. Konstan, J. Taylor-Cousar, I. Fajac +12 more

    2021Journal of Cystic Fibrosis18 citations Open access

    Semantic Scholar

    Save

21. Timing of hypertonic saline and airway clearance techniques in adults with cystic fibrosis during pulmonary exacerbation: pilot data from a randomised crossover study

    K. O'Neill, F. Moran, M. Tunney, J. Elborn +4 more

    2017BMJ Open Respiratory Research18 citations Open access

    Semantic Scholar

    Save

22. Isolation, cultivation, and application of primary respiratory epithelial cells obtained by nasal brushing, polyp samples, or lung explants

    A. Golec, I. Pranke, P. Scudieri, K. Hayes +6 more

    2022STAR Protocols16 citations Open access

    Semantic Scholar

    Save

23. SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network

    S. van Koningsbruggen-Rietschel, F. Dunlevy, V. Bulteel, D. Downey +1 more

    2020European Respiratory Journal16 citations Open access

    Semantic Scholar

    Save

24. Chronic lung disease in common variable immune deficiency (CVID): A pathophysiological role for microbial and non-B cell immune factors

    D. Mooney, D. Edgar, G. Einarsson, D. Downey +2 more

    2017Critical reviews in microbiology15 citations

    Semantic Scholar

    Save

25. The association between polypharmacy and medication regimen complexity and antibiotic use in bronchiectasis

    Maureen Spargo, C. Ryan, D. Downey, C. Hughes

    2018International Journal of Clinical Pharmacy11 citations Open access

    Semantic Scholar

    Save

26. Relative resistance index (RRI) – a scoring system for antibiotic resistance in Pseudomonas aeruginosa

    J. Ewing, J. McCaughan, J. E. Moore, D. Fairley +3 more

    2017British Journal of Biomedical Science11 citations Open access

    Semantic Scholar

    Save

27. Microscopic polyangiitis secondary to Mycobacterium abscessus in a patient with bronchiectasis: a case report

    C. Addy, G. Doran, A. Jones, G. Wright +2 more

    2018BMC Pulmonary Medicine10 citations Open access

    Semantic Scholar

    Save

28. 193 In vitro synergistic effect of NaCl and antibiotics against P. aeruginosa from cystic fibrosis patients

    A. Gramegna, B. Millar, M. Contarini, F. Blasi +3 more

    20178 citations Open access

    Semantic Scholar

    Save

29. Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis.

    N. Derichs, J. Taylor-Cousar, J. Davies, I. Fajac +18 more

    2021Journal of Cystic Fibrosis7 citations Open access

    Semantic Scholar

    Save

30. Laboratory Diagnosis and Characterization of Fungal Disease in Patients with Cystic Fibrosis (CF): A Survey of Current UK Practice in a Cohort of Clinical Microbiology Laboratories

    M. Boyle, J. Moore, J. Whitehouse, D. Bilton +1 more

    2018Mycopathologia7 citations Open access

    Semantic Scholar

    Save

31. Antimycobacterial activity of nonantibiotics associated with the polypharmacy of cystic fibrosis (CF) against mycobacterium abscessus

    Zara I Kirkwood, B. Millar, D. Downey, J. Moore

    2018International Journal of Mycobacteriology7 citations Open access

    Semantic Scholar

    Save

32. Competition between co-occurring invasive and native consumers switches between habitats

    Maureen Spargo, C. Ryan, D. Downey, C. Hughes

    20187 citations

    Semantic Scholar

    Save

33. P028 Riociguat for the treatment of adult Phe508del homozygous cystic fibrosis: efficacy data from the Phase II Rio-CF study

    J. Taylor-Cousar, E. Tullis, N. Derichs, J. Davies +17 more

    2018Journal of Cystic Fibrosis7 citations Open access

    Semantic Scholar

    Save

34. The Impact of Lung Proteases on Snake-Derived Antimicrobial Peptides

    Shannice Creane, Simon R. Carlile, D. Downey, S. Weldon +2 more

    2021Biomolecules6 citations Open access

    Semantic Scholar

    Save

35. Protecting clinical trials in cystic fibrosis during the SARS-CoV-2 pandemic: risks and mitigation measures

    S. van Koningsbruggen-Rietschel, F. Dunlevy, V. Bulteel, K. Hayes +6 more

    2021Trials6 citations Open access

    Semantic Scholar

    Save

36. WS06-1 Initial results evaluating combinations of the novel CFTR corrector PTI-801, potentiator PTI-808, and amplifier PTI-428 in cystic fibrosis subjects

    D. Downey, P. Flume, Manu Jain, I. Fajac +13 more

    2019Journal of Cystic Fibrosis6 citations Open access

    Semantic Scholar

    Save

37. WS11.5 Evaluation of combinations of the CFTR potentiator dirocaftor, corrector posenacaftor and amplifier nesolicaftor in cystic fibrosis subjects with two copies of the F508del mutation

    D. Downey, I. Fajac, P. Flume, M. O'Carroll +7 more

    2020Journal of Cystic Fibrosis5 citations Open access

    Semantic Scholar

    Save

38. INCREASING BURDEN OF ANTIMICROBIAL RESISTANCE IN PSEUDOMONAS AERUGINOSA FROM ADULT PATIENTS WITH CYSTIC FIBROSIS (CF) IN NORTHERN IRELAND: THEN AND NOW

    A. Gramegna, J. Moore, J. McCaughan, B. Millar +4 more

    2018Ulster medical journal5 citations

    Semantic Scholar

    Save

39. Clinimetric Properties of Outcome Measures in Bronchiectasis.

    J. Bradley, K. Ferguson, A. Bailey, K. O'Neill +11 more

    2022Annals of the American Thoracic Society4 citations Open access

    Semantic Scholar

    Save

40. Who’s at The Door? – Surface Contamination of Door Frames in a Single-Bedded In-Patient Adult Cystic Fibrosis (CF) Unit

    M. Furukawa, J. McCaughan, J. Stirling, B. Millar +7 more

    2020Ulster medical journal4 citations

    Semantic Scholar

    Save

41. Pseudomonas aeruginosa – Candida interplay: effect on in vitro antibiotic susceptibility of Pseudomonas aeruginosa when grown in the presence of Candida culture

    Rachael Mcilroy, B. Millar, D. Nelson, Alan Murphy +3 more

    2020British Journal of Biomedical Science4 citations

    Semantic Scholar

    Save

42. The role of inflammation in cystic fibrosis pulmonary exacerbations

    C. Houston, C. Taggart, D. Downey

    2020Expert Review of Respiratory Medicine4 citations

    Semantic Scholar

    Save

43. Gram negative infections in cystic fibrosis: a review of preventative and treatment options

    C. Addy, S. Caskey, D. Downey

    2020Expert Opinion on Orphan Drugs3 citations Open access

    Semantic Scholar

    Save

44. P021 A phase 3, open-label study of tezacaftor/ivacaftor (TEZ/IVA) therapy: interim analysis of pooled safety, and efficacy in patients homozygous for F508del-CFTR

    P. Flume, J. Lekstrom-Himes, R. Biner, C. Simard +4 more

    2018Journal of Cystic Fibrosis3 citations Open access

    Semantic Scholar

    Save

45. Immunodeficiency in Bronchiectasis

    T. Coulter, L. Devlin, D. Downey, J. Elborn +1 more

    20183 citations

    Semantic Scholar

    Save

46. Diagnostic agreement among experts assessing adults presenting with possible cystic fibrosis: need for improvement and implications for patient care

    A. Franciosi, A. Tanzler, Jodi L. Goodwin, P. Wilcox +5 more

    2022ERJ Open Research2 citations Open access

    Semantic Scholar

    Save

47. Letter to the editor: Challenges and opportunities in the development of future CFTR modulator options for people with CF.

    D. Downey, J. Taylor-Cousar

    2020Journal of Cystic Fibrosis2 citations Open access

    Semantic Scholar

    Save

48. P347 A survey of cardiovascular disease in UK cystic fibrosis centres

    D. Downey, J. Bengoechea, T. Curtis, D. Grieve +1 more

    2019Journal of Cystic Fibrosis2 citations Open access

    Semantic Scholar

    Save

49. Clinical Research Fellow

    C. Addy, J. Bradley, L. McGarvey, J. Elborn +1 more

    2019Ulster medical journal2 citations

    Semantic Scholar

    Save

50. WS15.6 A phase 3, open-label study of tezacaftor/ivacaftor (TEZ/IVA) therapy: interim analysis of pooled safety, and efficacy in patients heterozygous for F508del-CFTR and a residual function mutation

    P. Flume, C. Owen, R. Biner, C. Simard +4 more

    2018Journal of Cystic Fibrosis2 citations Open access

    Semantic Scholar

    Save